Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer

P. Viladlu, F. X. Bosch, X. Castellsagué, N. Muñoz, J. Escribà, E. Hamšíkova, V. Hofmannová, E. Guerrero, A. Izquierdo, C. Navarro, P. Moreo, I. Izarzugaza, N. Ascunce, M. Gili, M. T. Muñoz, L. Tafur, K. V. Shah, V. Vonka

Research output: Contribution to journalArticle

Abstract

Purpose: To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. Subjects and Methods: Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) an scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). Results: Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95% confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. Conclusion: The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.

Original languageEnglish (US)
Pages (from-to)610-619
Number of pages10
JournalJournal of Clinical Oncology
Volume15
Issue number2
StatePublished - Feb 1997
Externally publishedYes

Fingerprint

Squamous Cell Neoplasms
Human papillomavirus 16
Uterine Cervical Neoplasms
Peptides
Survival
Antibodies
DNA
Confidence Intervals
Recurrence
Papillomavirus E7 Proteins
Viral Load
Case-Control Studies
Cause of Death
Neoplasms
Epithelial Cells
Enzyme-Linked Immunosorbent Assay
Biopsy
Polymerase Chain Reaction
Mortality
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Viladlu, P., Bosch, F. X., Castellsagué, X., Muñoz, N., Escribà, J., Hamšíkova, E., ... Vonka, V. (1997). Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. Journal of Clinical Oncology, 15(2), 610-619.

Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. / Viladlu, P.; Bosch, F. X.; Castellsagué, X.; Muñoz, N.; Escribà, J.; Hamšíkova, E.; Hofmannová, V.; Guerrero, E.; Izquierdo, A.; Navarro, C.; Moreo, P.; Izarzugaza, I.; Ascunce, N.; Gili, M.; Muñoz, M. T.; Tafur, L.; Shah, K. V.; Vonka, V.

In: Journal of Clinical Oncology, Vol. 15, No. 2, 02.1997, p. 610-619.

Research output: Contribution to journalArticle

Viladlu, P, Bosch, FX, Castellsagué, X, Muñoz, N, Escribà, J, Hamšíkova, E, Hofmannová, V, Guerrero, E, Izquierdo, A, Navarro, C, Moreo, P, Izarzugaza, I, Ascunce, N, Gili, M, Muñoz, MT, Tafur, L, Shah, KV & Vonka, V 1997, 'Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer', Journal of Clinical Oncology, vol. 15, no. 2, pp. 610-619.
Viladlu, P. ; Bosch, F. X. ; Castellsagué, X. ; Muñoz, N. ; Escribà, J. ; Hamšíkova, E. ; Hofmannová, V. ; Guerrero, E. ; Izquierdo, A. ; Navarro, C. ; Moreo, P. ; Izarzugaza, I. ; Ascunce, N. ; Gili, M. ; Muñoz, M. T. ; Tafur, L. ; Shah, K. V. ; Vonka, V. / Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 2. pp. 610-619.
@article{b870c3250d8d441e85fb7df69c2069e5,
title = "Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer",
abstract = "Purpose: To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. Subjects and Methods: Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87{\%}), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) an scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). Results: Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95{\%} confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95{\%} CI, 1.2 to 37.6) and II (HRa = 5.9; 95{\%} CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95{\%} CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. Conclusion: The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.",
author = "P. Viladlu and Bosch, {F. X.} and X. Castellsagu{\'e} and N. Mu{\~n}oz and J. Escrib{\`a} and E. Hamš{\'i}kova and V. Hofmannov{\'a} and E. Guerrero and A. Izquierdo and C. Navarro and P. Moreo and I. Izarzugaza and N. Ascunce and M. Gili and Mu{\~n}oz, {M. T.} and L. Tafur and Shah, {K. V.} and V. Vonka",
year = "1997",
month = "2",
language = "English (US)",
volume = "15",
pages = "610--619",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer

AU - Viladlu, P.

AU - Bosch, F. X.

AU - Castellsagué, X.

AU - Muñoz, N.

AU - Escribà, J.

AU - Hamšíkova, E.

AU - Hofmannová, V.

AU - Guerrero, E.

AU - Izquierdo, A.

AU - Navarro, C.

AU - Moreo, P.

AU - Izarzugaza, I.

AU - Ascunce, N.

AU - Gili, M.

AU - Muñoz, M. T.

AU - Tafur, L.

AU - Shah, K. V.

AU - Vonka, V.

PY - 1997/2

Y1 - 1997/2

N2 - Purpose: To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. Subjects and Methods: Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) an scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). Results: Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95% confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. Conclusion: The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.

AB - Purpose: To assess whether human papillomavirus (HPV) DNA detection in cervical cancer specimens, or antibodies to selected HPV 16 peptides are predictors of tumor recurrence and long-term survival in patients with squamous cell invasive cervical cancer. Subjects and Methods: Four hundred seventy-one cases included in two population-based case-control studies underwent follow-up evaluation. The survival and cause of death were ascertained for 410 cases (87%), with a median follow-up time of 4.6 years after diagnosis. HPV DNA was assessed using an L1 polymerase chain reaction (PCR)-based system and Southern hybridization (SH) an scraped cytologic specimens or biopsies. HPV 16 antibodies to E2, L2, and E7 peptides were detected with enzyme-linked immunosorbent assay (ELISA). Results: Clinical stage was the only independent prognostic factor for recurrence or survival. Although seropositivity to HPV 16 E7/3 peptide predicted a twofold excess risk of mortality (adjusted hazards ratio [HRa] = 2.0; 95% confidence interval [CI], 1.2 to 3.3), the association was restricted to stage I (HRa = 6.6; 95% CI, 1.2 to 37.6) and II (HRa = 5.9; 95% CI, 2.1 to 16.5) patients. The presence of HPV DNA (HRa = 0.9; 95% CI, 0.5 to 1.5), different estimates of the HPV viral load and the HPV type identified were not predictors of tumor recurrence or survival. Conclusion: The presence of antibodies to HPV 16 E7 proteins is of prognostic value in early-stage cervical cancer. Our results provide strong evidence that detection and typing of HPV DNA in cervical cells or tissues is not a prognostic factor for recurrence or survival.

UR - http://www.scopus.com/inward/record.url?scp=0031037242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031037242&partnerID=8YFLogxK

M3 - Article

C2 - 9053484

AN - SCOPUS:0031037242

VL - 15

SP - 610

EP - 619

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -